The 2026 acne trial protocol tests standard therapy plus oral probiotic HEXBIO and topical mesenchymal-stem-cell secretome for mild-to-moderate acne vulgaris. Secretome here means a cell-derived topical formula used as an add-on, not a moisturizer or retinoid. BMJ Open published the phase 2 double-blind randomised controlled trial protocol on 4 June 2026, as described in the phase 2 protocol in BMJ Open. The plan assigns 64 patients to four treatment arms and measures change over 8 weeks.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What combination does the protocol test?
- Who takes part and what happens during 8 weeks?
- What did earlier probiotic acne trials find?
- What should people with acne-prone skin do now?
What combination does the protocol test?
BMJ Open states the trial adds two experimental products to standard acne care. Patients receive standard therapy plus active or placebo probiotic and active or placebo secretome.
That four-arm layout separates the effect of each add-on from the effect of the pair. All patients continue a standard acne regimen, so the trial tests extra benefit rather than a replacement.
Who takes part and what happens during 8 weeks?
BMJ Open states the trial randomises 64 male and female patients with inflammatory and non-inflammatory lesions. Each arm combines standard therapy with a different active or placebo pairing.
The U.S. National Library of Medicine PubMed record lists 8 weeks of treatment with pretest and posttest checks of acne severity, faecal microbiome restoration and related outcomes, detailed in the PubMed record. The linked registry entry titles the study Standard therapy and Secretome and HEXBIO in Acne Vulgaris and specifies baseline versus post-therapy measurement.
What did earlier probiotic acne trials find?
A December 2025 systematic review in Medicina pooled three double-blind acne randomised trials with 231 participants. It found oral probiotics modestly reduced inflammatory severity as a generally safe antibiotic-sparing adjunct.
Certainty in that review was low to moderate, so the result supports further testing rather than routine use. The new protocol extends that question by adding a topical secretome and by tracking gut microbiome changes alongside skin outcomes.
What should people with acne-prone skin do now?
The 2026 document is a protocol only, so BMJ Open states it proves design and intent rather than showing that the combination works. Its small size and short follow-up also limit generalisation to wider acne populations.
Readers should not treat marketed exosome or secretome skincare as FDA-approved acne therapy. The FDA states exosome products for clinical use are regulated as drugs or biologics requiring premarket review, following a safety notification after serious adverse events, explained in the FDA safety notification.
- Keep current prescription treatment unless a clinician changes it
- Bring the 8-week add-on design to a dermatology visit for discussion
- Ask about probiotic strain, topical ingredients, side effects and antibiotic need
- Avoid clinic or retail exosome facials sold as proven acne cures
You Might Also Like
- Skin Microbiome Outcomes in the 2026 Probiotic Acne Review: A Source-Checked 2026 Briefing for People With Acne-Prone Skin
- Probiotics for Acne in a 2026 Systematic Review and Meta-Analysis: A Source-Checked 2026 Briefing for People With Acne-Prone Skin
- The 2026 Global Delphi Consensus on Acne and the Microbiome: Why the Findings May Not Change Acne Care Yet for People With Acne-Prone Skin